EPIX Achieves Discovery Milestone in Collaboration with GlaxoSmithKline
News Aug 16, 2007
Using its proprietary, integrated computational-medicinal chemistry approach to drug discovery, EPIX has identified three lead candidates that will move forward into lead optimization in this first collaborative G-protein coupled receptor (GPCR) discovery program.
Under the collaboration, EPIX is entitled to receive a $3 million milestone payment from GSK in the next 30 days.
“We are extremely pleased with the progress of our collaboration with GSK,” stated Michael G. Kauffman, M.D., Ph.D., chief executive officer of EPIX.
“In addition to our joint focus on developing PRX-03140, our proprietary 5-HT4 agonist, for the treatment of Alzheimer’s disease, EPIX and GSK have agreed upon the three discovery program targets and are making significant progress on each program. We are on-schedule and expect to continue moving forward to achieve key milestones across all of our collaborative programs,” Kauffman added.
In December 2006, EPIX and GSK announced a worldwide multi-target strategic collaboration to discover, develop and market medicines targeting four G-protein coupled receptors (GPCRs) for the treatment of a variety of diseases, including EPIX’s novel 5-HT4 partial agonist program, PRX-03140, which is in early-stage clinical development for the treatment of Alzheimer's disease.
As part of the collaboration, EPIX received total initial payments of $35 million, including $17.5 million through the purchase of its common stock at a premium, and may be eligible to earn up to $1.2 billion in milestones across the four GPCR programs.
Under the collaboration, EPIX is also entitled to receive tiered double-digit royalties of sales by GSK on all collaboration-developed product sales. The alliance is conducted through GSK’s Center of Excellence for External Drug Discovery (CEEDD).
Stereochemistry is a science of reflection. Two chemical molecules with the same composition and structure, but with one as the mirror image of the other, can produce wildly varying effects. But University of Utah chemist Matt Sigman has been developing a way to get a better grasp on this tricky field of chemistry.READ MORE